详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes

47| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [2]The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China [3]Yifan Research & Development, Hefei, Anhui, China [4]Lanzhou University Second Hospital, Lanzhou, Gansu, China [5]The Affiliated Huaian No 1 People’s Hospital of Nanjing Medical University, Huaian, Jiangsu, China [6]The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China [7]The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China [8]Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China [9]The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China [10]The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China [11]The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China [12]Hengshui People’s Hospital, Hengshui, Hebei, China [13]West China Hospital of Sichuan University, Chengdu, Sichuan, China [14]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China [15]The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China [16]The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China [17]Cangzhou Central Hospital, Cangzhou, Hebei, China [18]The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China [19]The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China [20]The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China [21]Ningbo First Hospital, Ningbo, Zhejiang, China [22]Peking University Third Hospital, Beijing, China

出处：

DOI：

ISSN：

关键词： Chronic myeloid leukemia Arsenic Imatinib Efficacy and safety

摘要：

The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the efficacy of the arsenic realgar-indigo naturalis formula (RIF) plus imatinib with that of imatinib monotherapy in patients with newly diagnosed chronic phase CML (CP-CML).In this multicenter, randomized, double-blind, phase 3 trial, 191 outpatients with newly diagnosed CP-CML were randomly assigned to receive oral RIF plus imatinib (n = 96) or placebo plus imatinib (n = 95). The primary end point was the major molecular response (MMR) at 6 months. Secondary end points include molecular response 4 (MR4), molecular response 4.5 (MR4.5), progression-free survival (PFS), overall survival (OS), and adverse events.The median follow-up duration was 51 months. Due to the COVID-19 pandemic, the recruitment to this study had to be terminated early, on May 28, 2020. The rates of MMR had no significant statistical difference between combination and imatinib arms at 6 months and any other time during the trial. MR4 rates were similar in both arms. However, the 12-month cumulative rates of MR4.5 in the combination and imatinib arms were 20.8% and 10.5%, respectively (p = 0.043). In core treatment since the 2-year analysis, the frequency of MR4.5 was 55.6% in the combination arm and 38.6% in the imatinib arm (p = 0.063). PFS and OS were similar at five years. The safety profiles were similar and serious adverse events were uncommon in both groups.The results of imatinib plus RIF as a first-line treatment of CP-CML compared with imatinib might be more effective for achieving a deeper molecular response (Chinadrugtrials number, CTR20170221).© 2024. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2.7 最新[2023版] 3.1 最新五年平均 2.7 出版当年[2023版] 0 出版当年五年平均 2.7 出版前一年[2023版]

第一作者：

第一作者机构： [1]State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes

文献详情

相关文献